Reviewing Motif Bio plc (MTFB)’s and Dermira Inc. (NASDAQ:DERM)’s results

Both Motif Bio plc (NASDAQ:MTFB) and Dermira Inc. (NASDAQ:DERM) are Biotechnology companies, competing one another. We will contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Motif Bio plc N/A 0.00 17.03M -1.44 0.00
Dermira Inc. 7 -0.02 43.10M -5.34 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Motif Bio plc and Dermira Inc.


Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Motif Bio plc 10,283,816,425.12% 0% 0%
Dermira Inc. 582,432,432.43% -391.8% -53.3%

Analyst Ratings

The table shown features the ratings and recommendations for Motif Bio plc and Dermira Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Motif Bio plc 0 0 0 0.00
Dermira Inc. 0 0 1 3.00

Dermira Inc. on the other hand boasts of a $18.5 consensus target price and a 131.54% potential upside.

Insider and Institutional Ownership

Motif Bio plc and Dermira Inc. has shares held by institutional investors as follows: 6.46% and 80.11%. Comparatively, Dermira Inc. has 0.6% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Motif Bio plc -2.36% -5.74% -72.7% -93.75% -92.68% -90.47%
Dermira Inc. 5.51% -4.24% -16.18% 33.08% -4.55% 22.53%

For the past year Motif Bio plc has -90.47% weaker performance while Dermira Inc. has 22.53% stronger performance.


Motif Bio plc beats Dermira Inc. on 6 of the 11 factors.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.